Amgen GmbH speaks the language of biotech geeks, only with a German accent. Amgen GmbH is a German unit of US-based Amgen, the world's largest biotech company. The subsidiary was established in 1989 to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen and Aranesp, for the treatment of anemia in people with chronic kidney disease; Neupogen and Neulasta, to help restore white blood cell counts for cancer patients; and Enbrel, for the treatment of psoriasis and rheumatoid arthritis.

Renovo was established in 2000 by Professor Mark Ferguson and Doctor Sharon O'Kane. Renovo had its way, that famous scar on Harry Potter would be gone in no time. The pharmaceutical company develops drug products designed to prevent scarring caused by skin or cosmetic surgeries, eye injuries, adhesions, tendon and ligament damage, and nerve damage (no word yet on if it helps treat the blemishes of boy wizards). Renovo's chief product is Juvista, a trial stage drug that is injected into the edges of wounds to help prevent scars. The company also has three other pre-clinical drug products in development: Juvidex (for scar improvement), Prevascar (scar reduction), and Zesteem (skin healing).

Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France. Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications in France. Its Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides, and other large and small molecules injected subcutaneously. The company's Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement. Its products based on Medusa technology include Interferon-AlphaXL, an interferon-alpha 2b for the treatment of hepatitis C virus and various oncology applications; FT-105 basal insulin, a long-acting formulation of recombinant human insulin to insulin-dependent patients; and interleukin-2 for the treatment of renal cancer. The company's products based on Micropump technology comprise Coreg CR, an extended release formulation of carvedilol phosphate for use in the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction, and hypertension; and Asacard162.5mg, a controlled release formulation of aspirin, which provide therapy for cardiovascular treatment. It has strategic alliances with GlaxoSmithKline, Merck Serono, Wyeth Pharmaceuticals, Pfizer, Corning S.A., Servier, and Corning Incorporated.

lmmuCell Corporation company was founded in 1982 and is based in Portland, Maine. ImmuCell Corporation, an animal health biotechnology company, engages in the development, manufacture, and sale of products that improve animal health and productivity in the United States and internationally. It offers First Defense, an orally delivered scours preventive product that is manufactured from cows colostrums using proprietary vaccine and milk protein purification technologies. The company also provides products that aid in the management of inflammation of the mammary gland caused by bacterial infections, including Wipe Out Dairy Wipes, which consist of pre-moistened, biodegradable towelettes that are impregnated with Nisin to prepare the teat area of a cow in advance of milking; MASTiK, a mastitis antibiotic susceptibility test kit; and California Mastitis Test (CMT), which is performed at cow-side for early detection of mastitis. CMT can be used for bulk tank and individual cow sample monitoring, and for determining the quarter of the udder that is mastitic. In addition, it offers Rapid Johne's Test, which identifies cattle with symptomatic Johne's disease in a herd. Additionally, ImmuCell Corporation focuses on developing Mast Out, an intramammary infusion product containing Nisin for use in the treatment of mastitis in lactating dairy cows. It sells and markets its products primarily to veterinarians and producers in the dairy and beef industries.

Depomed, Inc. was founded in 1995 and is based in Menlo Park, California. Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. It markets GLUMETZA for the treatment of type 2 diabetes in the United States, Canada, and Korea; and Proquin XR for treatment of uncomplicated urinary tract infection in the United States. Depomed company's under development products comprise DM-5689, a Phase III clinical trial product for the treatment of menopausal hot flashes; DM-1796, a Phase III clinical trial product for the treatment of postherpetic neuralgia, as well as is in Phase II clinical trail for diabetic peripheral neuropathy; DM-3458, a Phase I clinical trial product for the treatment of gastroesophageal reflux disease; and DM-1992, a Phase I clinical trial product that targets Parkinson's disease. It has collaboration and license agreements with PharmaNova, Inc.; Solvay Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Covidien Ltd.; Santarus, Inc.; Teva Pharmaceuticals USA, Inc.; Patheon, Inc.; Biovail Laboratories Incorporated; LG Life Sciences, Ltd.; Watson Pharmaceuticals, Inc.; and Rottapharm/Madaus S.r.l. The company sells its products to wholesalers and retail pharmacies.

Essential Group, Inc. company was founded in 1994 and taken private in 2007. Essential Group (formerly AmericasDoctor) is helping medical researchers find a more advanced way to cure that bellyache. The company acts as a contract research organization (CRO) to handle everything needed in a clinical drug trial, including study design, patient recruitment, clinical monitoring, and writing up the findings. It conducts Phase I-IV trials in areas such as cardiology, gastroenterology, urology, and women's health through test sites across the US. Essential Group's primary clients are pharmaceutical and biotechnology companies.

Contract Pharmacal Corp. (CPC) is a full-service contract research organization serving pharmaceutical companies, retailers, and wholesalers worldwide. CPC manufactures dietary supplements, a variety of over-the-counter medications, and private label and generic prescription drugs. The company's prescription portfolio consists of mostly of prenatal and multi-vitamins, as well as urinary tract infection treatments. Production capabilities also include manufacturing tablets, gelatin capsules, softgels, and liquids that can be packaged in bottles, cans, blister pouches, and cartons. CPC (in business since 1971) is owned and operated by CEO Matt Wolf and the founding Wolf family.

Glycotex wants to see such creatures as ulcers, bed sores, and sunburns put on the Australian endangered species list. The biopharmaceutical company researches and develops products based on molecular glucan receptors that trigger the healing process. Connective tissue repair, skin ulcers, and bone fractures are primary recovery fields for its glucan receptor products. Glycotex's lead product candidate, MG3601, is a topical treatment for ulcers, and it has completed Phase II clinical trials. Other therapeutic candidates include Glucocol and Glucoprime, active ingredients designed to treat tendon regeneration and topical needs, respectively. Its parent company, Novogen, owns 84% of Glycotex.

Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Kailua-Kona, Hawaii. Mera Pharmaceuticals, Inc. primarily develops and commercializes natural products derived principally from microalgae using its patented photobioreactor technology known as the Mera Growth Module. Mera Pharmaceuticals company's product line consists of ASTAFACTOR, a nutraceutical and source of natural astaxanthin; and SALMON ESSENTIALS, a combination of astaxanthin and omega-3 fatty acids. It markets its products to retail outlets in Hawaii through distribution arrangements with established companies.

Seattle Genetics, Inc. company was founded in 1997 and is headquartered in Bothell, Washington. Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma under a special protocol assessment. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; and SGN-70, a humanized anti-CD70 antibody. In addition, its product candidates in development comprise SGN-75 for CD70-positive hematologic malignancies and solid tumors; AGS-5ADC for solid tumors; and SGN-19A for CD19-positive hematologic malignancies. It has a collaboration agreement with Genentech, Inc. to develop and commercialize Dacetuzumab; with Genentech, Inc., Bayer Pharmaceuticals Corporation, CuraGen Corporation, Progenics Pharmaceuticals, Inc., Daiichi Sankyo Co., Ltd., and MedImmune Inc. for the company's antibody-drug conjugates (ADC) technology; and an ADC co-development agreement with Agensys, Inc.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.